Acadia Pharmaceuticals (ACHC) Reports Q3 2025 Earnings Results
Acadia Pharmaceuticals (ACHC) reported Q3 2025 earnings with revenue of $851.6 million, a 4.4% increase year-over-year, but adjusted EBITDA fell to $173 million, below expectations. The company revised its full-year guidance downward for both revenue and adjusted EBITDA due to volume softness and other factors.
Topics: Bed Additions Capital Expenditures CTC Expansion Earnings Report EBITDA Guidance Revision Revenue Growth